Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Research & Development (2016 - 2025)

Historic Research & Development for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $3.5 million.

  • Heron Therapeutics' Research & Development fell 2228.44% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year decrease of 4433.28%. This contributed to the annual value of $16.7 million for FY2024, which is 5736.85% down from last year.
  • Heron Therapeutics' Research & Development amounted to $3.5 million in Q3 2025, which was down 2228.44% from $2.9 million recorded in Q2 2025.
  • Over the past 5 years, Heron Therapeutics' Research & Development peaked at $42.1 million during Q1 2022, and registered a low of -$13.7 million during Q4 2022.
  • For the 5-year period, Heron Therapeutics' Research & Development averaged around $14.6 million, with its median value being $8.8 million (2023).
  • Per our database at Business Quant, Heron Therapeutics' Research & Development crashed by 14759.84% in 2022 and then surged by 15676.25% in 2023.
  • Quarter analysis of 5 years shows Heron Therapeutics' Research & Development stood at $28.9 million in 2021, then tumbled by 147.6% to -$13.7 million in 2022, then soared by 156.76% to $7.8 million in 2023, then tumbled by 59.27% to $3.2 million in 2024, then grew by 9.19% to $3.5 million in 2025.
  • Its last three reported values are $3.5 million in Q3 2025, $2.9 million for Q2 2025, and $2.3 million during Q1 2025.